ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial

Abstract Background For patients with oesophagogastric adenocarcinoma, surgery is the only curative option and despite the use of multimodality therapy, which combines it with chemotherapy and/or radiotherapy, more than 50% of patients will relapse and die. Many UK patients present with advanced dis...

Full description

Bibliographic Details
Main Authors: Elizabeth Smyth, Kelly Cozens, Daniel Griffiths, Kathryn L. Clark, Sean Ewings, Russell Petty, Tim Underwood, Rebecca C. Fitzgerald, James Tanner, Olivier Giger, Shubha Anand, Gareth Griffiths
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Oesophagogastric adenocarcinoma
Immunotherapy
MGMT methylated
Phase II
Online Access:https://doi.org/10.1186/s12885-022-09891-9

Internet

https://doi.org/10.1186/s12885-022-09891-9

Similar Items